Stockscreener 앱 받기
3.74
2.75%
0.10
시간 외 거래:
3.71
-0.03
-0.80%
전일 마감가:
$3.64
열려 있는:
$3.67
하루 거래량:
1.87M
Relative Volume:
0.44
시가총액:
$608.42M
수익:
$400.57M
순이익/손실:
$9.21M
주가수익비율:
93.50
EPS:
0.04
순현금흐름:
$146.36M
1주 성능:
+11.31%
1개월 성능:
-16.61%
6개월 성능:
+240.00%
1년 성능:
+151.01%
1일 변동 폭
$3.56
$3.795
1주일 범위
$3.22
$3.795
52주 변동 폭
$0.5271
$5.78
아이언우드 제약 Stock (IRWD) Company Profile
명칭
Ironwood Pharmaceuticals Inc
전화
617-621-7722
주소
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
3.74 | 592.15M | 400.57M | 9.21M | 146.36M | 0.04 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.98 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.48 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
아이언우드 제약 Stock (IRWD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-04-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-09-09 | 개시 | Leerink Partners | Market Perform |
| 2024-08-08 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2024-01-17 | 개시 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Wells Fargo | Overweight |
| 2023-11-09 | 개시 | Jefferies | Buy |
| 2023-09-28 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-02 | 개시 | CapitalOne | Overweight |
| 2022-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-06-17 | 개시 | Northland Capital | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-02-25 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2019-01-24 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2018-11-07 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-11-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-07-23 | 개시 | H.C. Wainwright | Sell |
| 2018-05-09 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-01-05 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2017-12-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2017-07-21 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2017-05-03 | 개시 | Wells Fargo | Outperform |
| 2017-04-07 | 재확인 | Mizuho | Buy |
| 2017-02-22 | 재확인 | Barclays | Equal Weight |
| 2016-11-04 | 재확인 | Mizuho | Buy |
| 2016-10-24 | 재확인 | Wedbush | Neutral |
| 2016-10-10 | 재확인 | Mizuho | Buy |
| 2016-09-27 | 재확인 | WallachBeth | Hold |
모두보기
아이언우드 제약 주식(IRWD)의 최신 뉴스
US Stocks Recap: Does Ironwood Pharmaceuticals Inc have declining or rising EPSJuly 2025 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Gains Report: Can Ironwood Pharmaceuticals Inc stock double in the next yearPrice Action & Target Return Focused Stock Picks - baoquankhu1.vn
IRWD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
IRONWOOD PHARMACEUTICALS INC (IRWD) Earnings History & Surprises - ChartMill
IRWD Should I Buy - Intellectia AI
Ironwood Pharmaceuticals (NASDAQ:IRWD) Cut to "Hold" at Zacks Research - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Plays Key Role In Nasdaq Futures Healthcare - Kalkine Media
Jefferies Maintains Hold on Ironwood Pharmaceuticals (IRWD) Feb 26, 2026 - Meyka
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance - Yahoo Finance
Ironwood Pharmaceuticals (NASDAQ:IRWD) Posts Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide - Seeking Alpha
Jefferies raises Ironwood Pharmaceuticals stock price target on Linzess outlook - Investing.com Canada
IRWD Q4 Earnings and Revenues Fall Shy of Estimates, Stock Tanks - Finviz
IRWD: Analyst Raises Price Target and Maintains Rating | IRWD St - GuruFocus
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 9.5% on Analyst Upgrade - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target Raised to $10.00 at Citizens Jmp - MarketBeat
GSA Capital Partners LLP Has $405,000 Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD - MarketBeat
Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue - simplywall.st
Ironwood (IRWD) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ironwood Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Ironwood Pharmaceuticals Balances Growth Plans With Pricing Risks - TipRanks
Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Highli - GuruFocus
Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding - Stock Titan
Ironwood Pharmaceuticals (IRWD) officer sells shares to cover tax withholding - Stock Titan
Ironwood Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Ironwood Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:IRWD) 2026-02-25 - Seeking Alpha
Ironwood Pharmaceuticals Faces Tumultuous Week Amid Market Volatility - StocksToTrade
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap DownWhat's Next? - MarketBeat
Ironwood Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Ironwood Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Ironwood Pharmaceuticals Q4 2025 misses forecasts, shares drop - Investing.com Australia
IRWD: 2026 guidance targets >$1.1B LINZESS sales and pivotal apraglutide Phase III launch - TradingView
Form 8K Ironwood Pharmaceuticals Inc For: 25 February By Investing.com - Investing.com Australia
Ironwood Pharmaceuticals (IRWD) Targets Over $300M Adjusted EBIT - GuruFocus
Ironwood (IRWD) Reports Q4 Revenue Below Expectations - GuruFocus
Ironwood Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2026 - marketscreener.com
Ironwood Pharmaceuticals officially released its financial report for the fourth quarter and full year of 2025 today. - Bitget
IRONWOOD PHARMACEUTICALS ($IRWD) Releases Q4 2025 Earnings - Quiver Quantitative
Form 8K Ironwood Pharmaceuticals Inc For: 25 February - Investing.com India
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook - The AI Journal
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results - TradingView
Ironwood Pharmaceuticals (IRWD) posts 2025 results and raises 2026 EBITDA outlook - Stock Titan
Ironwood: Q4 Financial Overview - Bitget
Insights into Ironwood Pharmaceuticals's Upcoming Earnings - Benzinga
Rate Hike: Can Ironwood Pharmaceuticals Inc stock double in the next year2025 Key Lessons & Long-Term Growth Stock Strategies - baoquankhu1.vn
What's in Store for These 5 Medical Companies This Earnings Season? - TradingView
Ironwood Pharmaceuticals Faces Operational Challenges Following Third-Quarter Earnings - StocksToTrade
IRWD’s Strategic Moves Amid Market Dynamics - timothysykes.com
Insider sale notice: Ironwood Pharmaceuticals (NASDAQ: IRWD) lists RSU shares - Stock Titan
아이언우드 제약 (IRWD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
아이언우드 제약 주식 (IRWD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| John Minardo | Chief Legal Officer |
Feb 23 '26 |
Sale |
3.81 |
17,439 |
66,443 |
382,939 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug |
Feb 23 '26 |
Sale |
3.81 |
15,570 |
59,322 |
538,437 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,239 |
41,135 |
213,738 |
| Gaskins Tammi L | Chief Commercial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,287 |
39,193 |
224,977 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 24 '26 |
Sale |
3.66 |
103,526 |
378,905 |
1,489,002 |
| MCCOURT Thomas A | Chief Executive Officer |
Feb 23 '26 |
Sale |
3.81 |
94,757 |
361,024 |
1,592,528 |
| Martini Gregory S. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.66 |
11,457 |
41,933 |
160,601 |
| Martini Gregory S. | Chief Financial Officer |
Feb 23 '26 |
Sale |
3.81 |
10,487 |
39,955 |
172,058 |
| Silver Ronald | Principal Accounting Officer |
Feb 24 '26 |
Sale |
3.66 |
12,621 |
46,193 |
252,636 |
| Silver Ronald | Principal Accounting Officer |
Feb 23 '26 |
Sale |
3.81 |
11,552 |
44,013 |
265,257 |
0.18%
1.85%
자본화:
|
볼륨(24시간):